These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 23773867)
1. Waldenström's macroglobulinemia: treatment approaches for newly diagnosed and relapsed disease. Hodge LS; Ansell SM Transfus Apher Sci; 2013 Aug; 49(1):19-23. PubMed ID: 23773867 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770 [TBL] [Abstract][Full Text] [Related]
3. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120 [TBL] [Abstract][Full Text] [Related]
4. Waldenström's macroglobulinemia as a diagnostic challenge: case report. Budimir I; Nikolić M; Pusić MS; Hrabar D; Ljubicić N; Duvnjak M; Supanc V; Nikolac I; Babić N; Sokcević M Acta Clin Croat; 2014 Mar; 53(1):94-7. PubMed ID: 24974671 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443 [TBL] [Abstract][Full Text] [Related]
6. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119 [TBL] [Abstract][Full Text] [Related]
7. How we treat Waldenström's macroglobulinemia. Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. Kyle RA; Ansell SM; Kapoor P Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464 [TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of Waldenström's macroglobulinemia. Johnson SA Expert Rev Anticancer Ther; 2006 Mar; 6(3):329-34. PubMed ID: 16503850 [TBL] [Abstract][Full Text] [Related]
12. Novel agents in the treatment of Waldenström's macroglobulinemia. Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845 [TBL] [Abstract][Full Text] [Related]
13. Waldenström's macroglobulinemia. Dimopoulos MA; Anagnostopoulos A Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748 [TBL] [Abstract][Full Text] [Related]
14. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121 [TBL] [Abstract][Full Text] [Related]
15. Waldenstrom's macroglobulinemia in the era of immunotherapy. Vaxman I; Gertz M Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730 [TBL] [Abstract][Full Text] [Related]
16. Role of plasmapheresis in Waldenström's macroglobulinemia. Stone MJ; Bogen SA Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):238-40. PubMed ID: 23522642 [TBL] [Abstract][Full Text] [Related]
17. A review of Waldenstrom's macroglobulinemia. McDermott MK; Bell EM Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041 [TBL] [Abstract][Full Text] [Related]
18. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316 [TBL] [Abstract][Full Text] [Related]